Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Mano

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
NPJ Breast Cancer|September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINESibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
JCO Global Oncology|October 22, 2025
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care SystemCarlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira, et al.
Clinical Breast Cancer|August 7, 2025
Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of BrazilAline Coelho Gonçalves, Tomas Reinert, Heloisa Mussato Fernandes da Cruz, et al.
JCO Global Oncology|January 30, 2026
Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care SectorIvan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira, et al.
JCO Global Oncology|November 9, 2022
Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in BrazilCristiano A A Resende, Heloísa M Fernandes Cruz, Matheus Costa E Silva, et al.
Breast (Edinburgh, Scotland)|December 11, 2017
Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancerSaulo Brito Silva, Allan Andresson Lima Pereira, Gustavo Nader Marta, et al.
The Oncologist|March 29, 2022
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast BrazilMaryam Nemati Shafaee, Leonardo Roberto Silva, Susana Ramalho, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
NPJ Breast Cancer|September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINESibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
JCO Global Oncology|October 22, 2025
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care SystemCarlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira, et al.
Clinical Breast Cancer|August 7, 2025
Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of BrazilAline Coelho Gonçalves, Tomas Reinert, Heloisa Mussato Fernandes da Cruz, et al.
JCO Global Oncology|January 30, 2026
Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care SectorIvan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira, et al.
JCO Global Oncology|November 9, 2022
Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in BrazilCristiano A A Resende, Heloísa M Fernandes Cruz, Matheus Costa E Silva, et al.
Breast (Edinburgh, Scotland)|December 11, 2017
Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancerSaulo Brito Silva, Allan Andresson Lima Pereira, Gustavo Nader Marta, et al.
The Oncologist|March 29, 2022
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast BrazilMaryam Nemati Shafaee, Leonardo Roberto Silva, Susana Ramalho, et al.
Pageof 5